Search clinical trials for: polymerase chain reaction

Total 4911 results

University of Washington
GlaxoSmithKline

Recruiting

Niraparib and TSR-042 for the Treatment of BRCA-Mutated Unresectable or Metastatic Breast, Pancreas, Ovary, Fallopian Tube, or Primary Peritoneal Cancer

Anatomic Stage III Breast Cancer AJCC v8 | Prognostic Stage III Breast Cancer AJCC v8 | Anatomic Stage IV Breast Cancer AJCC v8 | Prognostic Stage IV Breast Cancer AJCC v8 | Metastatic Pancreatic Carcinoma | Stage III Pancreatic Cancer AJCC v8 | Stage IV Pancreatic Cancer AJCC v8 | Unresectable Pancreatic... and other conditions

United States
Sorrento Therapeutics, Inc.

Recruiting

Study of the Safety and Efficacy of STI-6129 in Patients With Relapsed or Refractory Systemic AL Amyloidosis

Light Chain (AL) Amyloidosis

United States
University of Pennsylvania

Recruiting

Molecular Imaging of the Underlying Mechanism of Cardiotoxicity in Patients With Light Chain Amyloidosis Using PET/CT

Cardiac Amyloidosis

United States
OHSU Knight Cancer Institute
AstraZeneca; Oregon Health and Science University

Recruiting

Olaparib in Combination With Either Durvalumab, Selumetinib, or Capivasertib or Ceralasertib Alone in Treating Patients With Metastatic Triple Negative Breast Cancer

Anatomic Stage IV Breast Cancer AJCC v8 | Metastatic Triple-Negative Breast Carcinoma

United States
National Cancer Institute (NCI)
NRG Oncology

Active, not recruiting

Comparison of Standard of Care Treatment With a Triplet Combination of Targeted Immunotherapeutic Agents

Ovarian Seromucinous Carcinoma | Recurrent Ovarian High Grade Serous Adenocarcinoma | Recurrent Platinum-Resistant Ovarian Carcinoma | Fallopian Tube Mucinous Adenocarcinoma | Recurrent Fallopian Tube Clear Cell Adenocarcinoma | Recurrent Fallopian Tube Endometrioid Adenocarcinoma | Recurrent... and other conditions

United States, Puerto Rico
University of Washington
AstraZeneca

Active, not recruiting

Durvalumab and Olaparib for the Treatment of Prostate Cancer in Men Predicted to Have a High Neoantigen Load

Biochemically Recurrent Prostate Carcinoma | Prostate Adenocarcinoma

United States
National Cancer Institute (NCI)
NRG Oncology

Active, not recruiting

Testing the Combination of Olaparib and Durvalumab, Cediranib and Durvalumab, Olaparib and Capivasertib, and Cediranib Alone in Recurrent or Refractory Endometrial Cancer Following the Earlier Phase of the Study That Tested Olaparib and Cediranib in Comparison to Cediranib Alone, and Olaparib Alone

Endometrial Mixed Cell Adenocarcinoma | Endometrial Serous Adenocarcinoma | Endometrial Undifferentiated Carcinoma | Stage IV Uterine Corpus Cancer AJCC v8 | Endometrial Adenocarcinoma | Endometrioid Adenocarcinoma

United States, Canada
National Cancer Institute (NCI)

Active, not recruiting

Testing the Combination of the Anti-cancer Drugs Copanlisib, Olaparib, and MEDI4736 (Durvalumab) in Patients With Advanced Solid Tumors With Selected Mutations

Advanced Malignant Solid Neoplasm | Unresectable Malignant Solid Neoplasm | Metastatic Malignant Solid Neoplasm

United States
National Cancer Institute (NCI)

Active, not recruiting

Cediranib Maleate and Olaparib Compared to Bevacizumab in Treating Patients With Recurrent Glioblastoma

Recurrent Glioblastoma

United States
OHSU Knight Cancer Institute
Oregon Health and Science University

Terminated

Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial

Primary Myelofibrosis | Anemia | Recurrent Hodgkin Lymphoma | Refractory Hodgkin Lymphoma | Anatomic Stage IV Breast Cancer AJCC v8 | Recurrent Acute Myeloid Leukemia | Recurrent Myelodysplastic Syndrome | Refractory Acute Myeloid Leukemia | Refractory Chronic Myelomonocytic Leukemia | Refractory Myelodysplastic... and other conditions

United States
Roswell Park Cancer Institute
AstraZeneca

Active, not recruiting

Olaparib, Durvalumab, and Tremelimumab in Treating Patients With Recurrent or Refractory Ovarian, Fallopian Tube or Primary Peritoneal Cancer With BRCA1 or BRCA2 Mutation

BRCA1 Gene Mutation | BRCA2 Gene Mutation | Recurrent Fallopian Tube Carcinoma | Recurrent Ovarian Carcinoma | Recurrent Primary Peritoneal Carcinoma | Ovarian Serous Adenocarcinoma

United States
OHSU Knight Cancer Institute
Genentech, Inc.; Oregon Health and Science University

Withdrawn

SMMART Adaptive Clinical Treatment (ACT) Trial

Anatomic Stage III Breast Cancer AJCC v8 | Recurrent Ovarian Carcinoma | Anatomic Stage IV Breast Cancer AJCC v8 | Advanced Malignant Solid Neoplasm | Advanced Pancreatic Carcinoma | Stage II Pancreatic Cancer AJCC v8 | Stage III Pancreatic Cancer AJCC v8 | Stage IV Pancreatic Cancer AJCC v8 | Recurrent... and other conditions

United States
Mayo Clinic
National Cancer Institute (NCI)

Active, not recruiting

Niraparib and Dostarlimab for the Treatment of Germline or Somatic BRCA1/2 and PALB2 Mutated Metastatic Pancreatic Cancer

Stage IV Pancreatic Cancer AJCC v8 | Metastatic Pancreatic Ductal Adenocarcinoma

United States
M.D. Anderson Cancer Center

Active, not recruiting

Niraparib and Dostarlimab for the Treatment of Small Cell Lung Cancer and Other High-Grade Neuroendocrine Carcinomas

Stage III Lung Cancer AJCC v8 | Stage IIIA Lung Cancer AJCC v8 | Stage IIIB Lung Cancer AJCC v8 | Neuroendocrine Carcinoma | Stage IIIC Lung Cancer AJCC v8 | Lung Small Cell Carcinoma

United States
Eastern Cooperative Oncology Group
National Cancer Institute (NCI)

Terminated

Amifostine and Melphalan in Treating Patients With Primary Systemic Amyloidosis Who Are Undergoing Peripheral Stem Cell Transplantation

Multiple Myeloma and Plasma Cell Neoplasm | Drug/Agent Toxicity by Tissue/Organ

United States
SWOG Cancer Research Network
National Cancer Institute (NCI)

Completed

Lung-MAP: Biomarker-Targeted Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer

Recurrent Squamous Cell Lung Carcinoma | Stage IV Squamous Cell Lung Carcinoma AJCC v7

United States, Canada
National Cancer Institute (NCI)
NRG Oncology

Completed

Carboplatin, Paclitaxel, Bevacizumab, and Veliparib in Treating Patients With Newly Diagnosed Stage II-IV Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer

Ovarian Endometrioid Adenocarcinoma | Ovarian Undifferentiated Carcinoma | Fallopian Tube Carcinoma | Ovarian Carcinoma | Ovarian Clear Cell Adenocarcinoma | Ovarian Mucinous Adenocarcinoma | Fallopian Tube Transitional Cell Carcinoma | Ovarian Transitional Cell Carcinoma | Fallopian Tube Clear Cell... and other conditions

United States
OHSU Knight Cancer Institute
Oregon Health and Science University; Prospect Creek Foundation

Completed

Olaparib and Durvalumab in Treating Participants With Metastatic Triple Negative Breast Cancer

Anatomic Stage IV Breast Cancer AJCC v8 | Prognostic Stage IV Breast Cancer AJCC v8 | Estrogen Receptor Negative | HER2/Neu Negative | Progesterone Receptor Negative | Triple-Negative Breast Carcinoma

United States
Centre Henri Becquerel

Unknown

Detection of Recurrent Mutations in Waldenström's Disease (DigiWAL)

Waldenstrom's Disease

France
National Cancer Institute (NCI)
NRG Oncology

Completed

Pegylated Liposomal Doxorubicin Hydrochloride, Carboplatin, Veliparib, and Bevacizumab in Treating Patients With Recurrent Ovarian Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer

Recurrent Fallopian Tube Carcinoma | Recurrent Ovarian Carcinoma | Recurrent Primary Peritoneal Carcinoma | Ovarian Clear Cell Cystadenocarcinoma | Ovarian Endometrioid Adenocarcinoma | Ovarian Seromucinous Carcinoma | Ovarian Serous Cystadenocarcinoma | Undifferentiated Ovarian Carcinoma

United States
University Hospital, Toulouse

Completed

Detection of Human Papillomavirus in Polymerase Chain for Suspicious Lesions of the Amygdala: Concordance Smear-Biopsy (HPV-BIOFRO)

Human Papillomavirus

France
Mette Munk Lauridsen
Odense University Hospital; Region of Southern Denmark; Hospital of South West...

Completed

Diagnosis of Covert/Minimal Hepatic Encephalopathy by Means of Continuous Reaction Time Measurement

Liver Cirrhosis | Hepatic Encephalopathy

Denmark
Gilead Sciences

Completed

A Study of Response-Guided Duration of Combination Therapy With GS-9451, Pegasys® and Copegus® With and Without Tegobuvir (GS-9190) in Previously Untreated Subjects With Genotype 1 Chronic Hepatitis C

Hepatitis C, Chronic

United States, United Kingdom, France, Germany, Netherlands, Belgium, Austria, Poland
The Baruch Padeh Medical Center, Poriya
Clalit Health Services

Unknown

Effectiveness of Intrapartum Group B Streptococcus (GBS) Polimerase Chain Reaction Reaction (PCR) Screening

GBS
TC Biopharm

Not yet recruiting

ACHIEVE2 - Safety and Preliminary Efficacy of Intravenous TCB008 in Patients With Relapse or Refractory Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)/AML (ACHIEVE2)

Acute Myeloid Leukemia | Myelodysplastic Syndromes
Dickinson College

Not yet recruiting

Experiment Among Smokers in Which Two Variables Are Manipulated: Ostracism and Concealability

Ostracism
Medical University of South Carolina

Not yet recruiting

tFUS to Enhance Alertness and Performance

Reaction Time | Alertness

United States
Yongyong MA

Recruiting

Daratumumab/Daratumumab and Hyaluronidase-fihj in Combination With Pomalidomide and Dexamethasone for the Treatment of Patients With Newly Diagnosed AL Amyloidosis: a Prospective, Multicenter, Single-arm Study

Amyloid Light-chain Amyloidosis

China
Beni-Suef University

Not yet recruiting

Manual Diaphragm Release on Stepping Reaction Time in Chronic Obstructive Pulmonary Disease

Respiratory Disease
University of California, Irvine
Eurofins Viracor

Not yet recruiting

Prospect Eval of Efficacy of CMV-TCIP Direct Letermovir Prophylax After Allogen Hemato Cell Transpla

CMV | Allogeneic Stem Cell Transplantation

United States
Ruijin Hospital

Not yet recruiting

CMV-specific T Cell Immunity Test Indicated Prophylaxis of Letermovir After All-HSCT

Hematologic Malignancy
Istanbul University - Cerrahpasa (IUC)

Recruiting

The Open Kinetic Chain and Closed Kinetic Chain Strengthening Exercises in Degenerative Meniscus Tears

Knee Pain Swelling | Meniscus Tear | Degenerative Disease

Turkey
Dr. George Luciuk

Recruiting

Effects of Inhaled Epinephrine on Systemic Allergic Reactions During Allergy Testing Immunotherapy or Oral Challenges

Hypersensitivity | Anaphylaxis

Canada
The First Hospital of Jilin University

Not yet recruiting

Adebrelimab Plus Chemotherapy, Bevacizumab and Fluzoparib in Platinum-Sensitive Relapsed Ovarian Cancer

Platinum-sensitive Relapsed Ovarian Cancer
Cairo University

Not yet recruiting

Radiographic Assessment of Bone Gain Following Sinus Lifting With Simultaneous Implant Placement Using Crestal Approach With Membrane Control Technique for Bone Augmentation of Atrophied Maxillary Posterior Ridge

Implant Site Reaction | Maxillary Deficiency
Academisch Medisch Centrum - Universiteit van Amsterdam...

Not yet recruiting

Comparison of the Proteome in ICU Patients in Search for TRALI Biomarkers (CURIE)

ARDS, Human | Transfusion-Related Acute Lung Injury
University of Nottingham
Nottingham University Hospitals NHS Trust; Ipsen; National Institute for Health... and other collaborators

Recruiting

Drug-induced Liver Injury: Itching Study

Pruritus | Drug Induced Liver Injury

United Kingdom
Institut de cancérologie Strasbourg Europe

Not yet recruiting

Role of Sodium-glucose Linked Transporter 2 (SGLT2) and Its Inhibitor Over CARdiotoxicity Induced by Anthracyclines and Breast Cancer Tumorigenesis SCARA-B (SCARA-B)

Breast Neoplasms

France
Fondazione Policlinico Universitario Agostino Gemelli...

Not yet recruiting

Respiratory Trends During Blood Transfusions in Newborns. (ARTE)

Respiratory Complication | Respiratory Morbidity | Blood Transfusion Complication | Blood Transfusion Associated Adverse Reactions

Italy
Peking University Third Hospital

Recruiting

The Preventive Effect of Chemotherapy-induced Hand-foot Syndrome

Cancer

China
Australasian Gastro-Intestinal Trials Group
AstraZeneca; Wayne Elphinstone Research Fund

Not yet recruiting

Phase II Study of the Combination of Durvalumab (MEDI4736) (PDL1 Inhibitor) and Olaparib (PARP Inhibitor) in Advanced Cholangiocarcinoma After Initial Chemotherapy and Durvalumab (BIL-PPP)

Cholangiocarcinoma

Australia
Anhui Provincial Hospital

Recruiting

Effect of Letermovir Prophylaxis on CMV-specific Immune Reconstitution Post UCBT

Cytomegalovirus Infection Reactivation

China
AAADRS Clinical Research Center

Recruiting

FeNO as a Marker of Allergic Reactions to OFC and Response of OMA Treatment in Multiple FA

Food Allergy

United States
EMD Serono Research & Development Institute, Inc.
Merck KGaA, Darmstadt, Germany

Not yet recruiting

Tuvusertib Combined With Niraparib or Lartesertib in Participants With Epithelial Ovarian Cancer (DDRiver EOC 302)

Ovarian Cancer

United States, Germany
Tufts University

Not yet recruiting

Systemic Absorption of Dexamethasone Oral Rinse in Patients With Oral Lichen Planus

Oral Lichen Planus | Oral Lichenoid Reaction

United States
Imperial College London

Recruiting

Routinely Collected Clinical Data and Evaluation of Antimicrobial Target Attainment (DATATDM)

Pharmacokinetics | Drug-Related Side Effects and Adverse Reactions | Infections, Bacterial | Drug Monitoring

United Kingdom
Tanta University

Not yet recruiting

Evaluation of the Possible Safety and Efficacy of Dapagliflozin in the Prophylaxis of Doxorubicin-Induced Cardiotoxicity

Breast Cancer | Doxorubicin Induced Cardiomyopathy

Egypt
Hospital Universitario 12 de Octubre

Not yet recruiting

Registry of Patients in Shock Treated With Vasopressin

Shock | Vasopressor Adverse Reaction | Vasopressin Causing Adverse Effects in Therapeutic Use | Vasopressin Deficiency

Spain
Tongji Hospital

Not yet recruiting

Paradoxical Reactions of Remimazolam in Pediatric Painless Gastrointestinal Endoscopy

Endoscopy, Gastrointestinal
Jeffrey Zonder

Not yet recruiting

DapagliFLOzin in Renal AL Amyloidosis (FLORAL) (FLORAL)

Renal AL Amyloidosis

United States

Search clinical trials for: polymerase chain reaction

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Lebanon

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations